Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

What this study is about

A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.

Who can join (things the study team will check)

✅ You may be able to join if…

• Age ≥18 years;
• Admitted to an ICU with one or more of the following:
  • Non-invasive ventilation (including CPAP, Bipap and high flow oxygen (>10L/min) or invasive mechanical ventilation with an expected duration >24 hours for respiratory failure (hypercarbic or hypoxic)
  • Vasopressor or inotropic support with an expected duration of >24 hours
  • Cardiac arrest
• Continuous cardiac monitoring.

🚫 You may not be able to join if…

• Receiving ICU intervention (Non-invasive ventilation (including high flow nasal canula), invasive mechanical ventilation or inotropic support) for >18 hours
• Receiving IMV for airway protection only (for example, isolated head trauma)
• Active atrial fibrillation at the time of enrolment
• On oral or continuous infusion of Amiodarone
• Unlikely to survive >24 hours or palliative patients
• Cardiac surgery patients
• Patients requiring parenteral magnesium therapy (e.g. pre-eclampsia, asthma)
• Patients receiving dialysis
• Positive pregnancy test (females <50 years old)
• Previously enrolled in this trial
• Treating physician refuses enrollment

Where this trial is running

• St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada
• Kingston Health Sciences Centre, Kingston, Ontario, Canada
• The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
• The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada

Who to contact

Miranda Hunt · 613 549 6666 · miranda.hunt@kingstonhsc.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05829317.